<DOC>
	<DOCNO>NCT02039765</DOCNO>
	<brief_summary>To characterize plasma pharmacokinetics safety profile brimonidine follow single dose 4 time per day ( QID ) dose brimonidine tartrate ophthalmic solution 0.025 % 7 day healthy , adult subject .</brief_summary>
	<brief_title>Pharmacokinetics Safety Topical Administration Brimonidine Tartrate Ophthalmic Solution 0.025 % .</brief_title>
	<detailed_description />
	<mesh_term>Hyperemia</mesh_term>
	<mesh_term>Brimonidine Tartrate</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>ocular health within normal limit . blood ( hematology , blood chemistry ) urine analysis within normal limit . body weight within 15 % ideal weight know contraindication sensitivity use investigational drug ( ) component , medication require protocol ; active systemic ocular disorder refractive disorder . presence abnormality lid , ocular surface , lacrimal duct system Investigator 's opinion could affect ophthalmic drop absorption . history chronic alcohol consumption . consume alcohol and/or caffeine xanthine containing product within 48 hour prior dose Visit 1 anticipate use study . history tobacco , nicotine , nicotine contain product use within last year prior Visit 2 ; significant weight change ( 10 pound ) within 60 day prior Visit 2 ; blood donation equivalent blood loss 450 ml , within 60 day prior Visit 2 ; abnormal blood pressure ( define ≤ 90 ≥ 160 ( systolic ) measure mmHg ≤ 60 ≥ 100 ( diastolic ) measure mmHg ) ; intraocular pressure ( IOP ) less 5 mmHg great 22 mmHg normal IOP diagnosis glaucoma .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Ocular Redness</keyword>
</DOC>